BioSpace News Archive

CB Scientific. Inc. has announced it will convene a Special Stockholder Meeting in order to gain approval to implement a number of significant enhancements which management believes will better position CBSC to attain its stated business objectives.

Recursion, a clinical-stage biotechnology company decoding biology to radically improve lives by industrializing drug discovery, development and beyond through disruptive innovation, announced a deepening of its neuroscience expertise with key hires in human induced pluripotent stem cell biology, translational neuroscience and clinical development.

Hepion Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation for the Company’s lead drug candidate, CRV431, for the treatment of NASH.

Organovo Holdings, Inc., provided a business overview and progress update, and announced it is on track to establish its first models of inflammatory bowel disease in 2022 using its 3D bioprinting and other 3D tissue technologies.

AmMax Bio, Inc. today announced that it will host a key opinion leader (KOL) webinar on AMB-05X on Tuesday, December 7th @ 1pm ET

Takeda Pharmaceutical Company Limited announced that it is enhancing its Corporate Social Responsibility Program in the U.S., making an initial commitment of $20 million its first year supporting organizations in the U.S. to help improve equity among underrepresented communities in the areas of health, education, the environment and access to nutrition/food.

Better Therapeutics, Inc. today announced the appointment of Deepti Sodhi Jaggi, PharmD, as its Chief Strategy Officer.

Immunexpress, Inc., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced that SeptiCyte® RAPID has received 510(k) clearance from the U.S. Food and Drug Administration (FDA).

Abivax SA, a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, reports the good tolerability and promising signals of clinical benefit resulting from its clinical phase 1/2 study conducted with ABX196.

Today EpiVax, Inc. (“EpiVax”) confirmed that the company’s EPV-CoV-19 vaccine epitopes are 98.2% conserved in the new Omicron SARS-CoV-2 variant. EpiVax and EpiVax Therapeutics, Inc. (“EVT”) are also affirming commitment to move the novel T cell epitope vaccine into the clinic in 2022.